AbbVie Reaches Deal With Trump Administration on Drug Pricing

AbbVie has announced a voluntary agreement with the Trump administration aimed at expanding access and affordability of medicines for Americans while reinforcing the company’s long-term commitment to U.S.-based pharmaceutical innovation. The agreement aligns with the administration’s stated drug pricing priorities and includes significant investment pledges tied to research, development, and manufacturing in the United States.

Under the terms of the agreement, AbbVie will continue to provide low drug prices within the Medicaid program while committing to invest $100 billion in U.S.-based research and development and capital projects over the next decade. These investments will include expanded manufacturing capabilities, supporting domestic production and strengthening the U.S. pharmaceutical supply chain.

In addition, AbbVie plans to broaden its direct-to-patient offerings through the TrumpRx initiative. This expansion is expected to improve access to several widely used medicines, including ALPHAGAN®, COMBIGAN®, HUMIRA®, and SYNTHROID®, which collectively are prescribed to millions of Americans. By leveraging direct distribution models, AbbVie aims to reduce barriers for patients navigating the healthcare system and improve affordability at the point of access.

AbbVie Chairman and Chief Executive Officer Robert A. Michael said the agreement reflects the company’s mission to deliver meaningful benefits to patients while sustaining innovation. He noted that AbbVie employs approximately 29,000 people in the United States and provides treatments to around 16 million Americans each year, giving the company a firsthand view of access and affordability challenges within the healthcare system. According to Michael, the agreement allows AbbVie and the administration to move beyond policies that could undermine American pharmaceutical innovation while still delivering cost savings to patients.

The agreement was enabled in part by exemptions from tariffs and future price mandates, as well as continued government efforts to encourage global pricing structures that recognize the value of U.S. medical innovation. While AbbVie confirmed that the agreement addresses all four of the administration’s drug pricing priorities, additional details of the arrangement remain confidential.

Overall, the deal underscores AbbVie’s effort to balance drug affordability initiatives with sustained investment in innovation and domestic manufacturing.